.jpeg)
Cobenfy(KarXT)的副作用和不良反应
The following content only reflects the range of side effects of Cobenfy (KarXT) in overseas registered countries, and does not represent the approved range of use in mainland China. Please do not make any treatment decisions based on this.
Cobenfy (KarXT) side effects
The most common adverse reactions (≥5%): nausea, indigestion, constipation, vomiting, hypertension, abdominal pain, diarrhea, tachycardia, dizziness, gastroesophageal reflux disease.
Side Effect Management for Medical Professionals
1. General Adverse Events
The most common adverse reactions are nausea, indigestion, constipation, vomiting, hypertension, abdominal pain, diarrhea, tachycardia, dizziness and gastroesophageal reflux disease.
2. Cardiovascular system
(1), very common (10% or more): hypertension (11%).
(2). Common (1% to 10%): tachycardia/increased heart rate, orthostatic hypotension.
(3) Post-marketing reports: chest pain, hypertensive crisis, palpitations, supraventricular tachycardia, syncope.
3. Cutaneous system
Post-marketing reports: rash, angioedema, Stevens-Johnson syndrome.
4. Gastrointestinal system
(1), very common (10% or more): nausea (19%), indigestion/esophageal discomfort (18%), constipation (17%), vomiting (15%).
(2) Common (1% to 10%): abdominal pain, diarrhea, gastroesophageal reflux disease, dry mouth, excessive salivation.
(3). Post-marketing report: gastritis.
5. Genitourinary system
Common (1% to 10%): urinary retention.
The pictures come from public channels (such as the official website of the FDA, the official website of the original drug manufacturer, etc.) and are for reference only.
6. Hepatobiliary system
(1), common (1% to 10%): elevated liver enzymes.
(2). Frequency not reported: biliary obstruction.
7. Anaphylaxis
Post-marketing report: allergic reaction (including angioedema of the face, lips, tongue and/or throat).
8. Musculoskeletal system
Post-marketing report: rhabdomyolysis.
9. Nervous system
(1), common (1% to 10%): dizziness, drowsiness, extrapyramidal symptoms (non-akathisia).
(2), frequency not reported: anticholinergic central nervous system effects.
(3) Post-marketing report: confusion, delirium, dizziness, hallucinations.
10. Ocular system
(1), common (1% to 10%): blurred vision.
(2). Post-marketing report: visual abnormalities.
11. Respiratory system
Common (1% to 10%): Cough/sputum production.
[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
